Tom Murphy's profile photo

Tom Murphy

Indianapolis

National Health Writer at Associated Press

Associated Press health care writer. Tries to make sense of health care and why it all costs so much. Retweets are just stuff I think you might want to read.

Featured in: Favicon apnews.com Favicon msn.com Favicon businessinsider.com Favicon independent.co.uk Favicon washingtonpost.com Favicon time.com Favicon usatoday.com Favicon cbsnews.com Favicon yahoo.com (+11) Favicon go.com

Articles

  • 1 week ago | ksat.com | Tom Murphy

    Published: April 17, 2025 at 6:14 AMUpdated: April 17, 2025 at 6:36 AMSign up for our NewslettersPublished: April 17, 2025 at 6:14 AMUpdated: April 17, 2025 at 6:36 AMUnitedHealth chopped its 2025 forecast after being surprised by care use from its Medicare Advantage customers in a worse-than-expected first quarter. Shares of the health care giant tumbled early Thursday, and the report rattled insurance stocks across the sector.

  • 1 week ago | yahoo.com | Tom Murphy

    TOM MURPHYUpdated Thu, April 17, 2025 at 11:14 AM UTC3 min readA surprising cost spike from Medicare Advantage plans helped push UnitedHealth shares into a dive Thursday, after the health care giant said it was chopping its 2025 forecast following a worse-than-expected first quarter. The company's stock shed more than $100 in value after markets opened Thursday, and the report rattled other insurance stocks.

  • 1 week ago | citizentribune.com | Tom Murphy

    Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment.

  • 1 week ago | yahoo.com | Tom Murphy

    TOM MURPHYUpdated Wed, April 16, 2025 at 1:13 PM UTC2 min readEuropean regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer and then reconsidered it. The infused treatment from Japanese drugmaker Eisai and Biogen received approval for patients in early stages of the fatal, mind-robbing disease.

  • 1 week ago | twincitiesbusinessradio.com | Tom Murphy

    European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer and then reconsidered it. The infused treatment from Japanese drugmaker Eisai and Biogen received approval for patients in early stages of the fatal, mind-robbing disease. The decision applies to all 27 members of the European Union plus Norway, Iceland and Liechtenstein, the drugmakers said late Tuesday.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
2K
Tweets
5K
DMs Open
Yes
Tom Murphy
Tom Murphy @thpmurphy
9 Apr 25

RT @jcohenap: Trump administration appeals court decision ordering AP journalists back into White House events https://t.co/GENsQadvcs http…

Tom Murphy
Tom Murphy @thpmurphy
9 Apr 25

RT @seungminkim: 🚨 WASHINGTON (AP) — Trump says he's backing down on most nations' tariffs for 90 days amid market meltdown, but he's raisi…

Tom Murphy
Tom Murphy @thpmurphy
9 Apr 25

RT @AP: The Associated Press wins reinstatement to White House events after judge rules government can’t bar its journalists, citing the 1s…